Spots Global Cancer Trial Database for Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Official Title: Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Study ID: NCT00171873
Conditions
Study Description
Brief Summary: Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Bochum, , Germany
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Halle, , Germany
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Kiel, , Germany
Novartis Investigative Site, Leipzig, , Germany
Novartis Investigative Site, Mainz, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Munchen, , Germany
Contact Details
Name: Rudolf Arnold, MD, Prof
Affiliation: Philipps University Marburg Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
